Kornimate/medical-research-clean huggingface dataset:
efficacy of the treatment of plantar orthoses with extracorporeal shock wave therapy in plantar fasciitis

Conditions: Fasciitis, Plantar, Chronic

Summary: plantar fasciitis is inflammation of plantar fascia. it arises from degeneration and chronic inflammation. treatment of plantar fasciitis contains conservative methods like rest, body weight control, stretching exercise, non-steroidal anti-inflammatory drugs and arch supports. eswt has commonly been used for the treatment of plantar fasciitis. the shock waves can be radial or focused. the aim of this study was to evaluate the effectiveness of the adjuvant use of plantar orthoses in the process of plantar fasciitis when extracorporeal shock waves are applied. the hypothesis porposed was that the use of extracorporeal shock waves together with the use of custom foot orthotics improves the symptoms produced by plantar fasciitis. this study is planned as double-blind, randomized controlled trial. participants are randomly allocated to two groups: the eswt group and the custom foot orthotics and eswt group. radial eswt will be applied in this study. the people receiving the therapy and the people assessing the outcomes are blinded . both group will recieve eswt one session per week for three weeks. each session will last for 2-5 minutes. the primary outcome measure of this study is change in heel pain of affected side assessed using visual analog scale. the secondary outcome measure is roles y maudsley scores. the primary endpoint of this study is to determine a decrease in pain score according to visual analog scale.


Eligibility criteria:
inclusion criteria: * age between 18 - 65 years * able to understand the explanations about the potential benefits and risks of participating in the study * both genders * diagnosis of chronic plantar fasciitis * duration of symptoms equal or superior to 6 months at the time of enrollment * foot posture index ≥ +6 (pronated foot in one or both feet). exclusion criteria: * being younger than 18 years of age * previous treatments with shock wave devices * previous surgery on the painful heel; history of calcaneus fracture * any inflammation at the level of the ankle * infection in the treated area * patients with diabetes mellitus or cardiac or respiratory disease * osteomyelitis * patients on anticoagulant drugs * pregnancy * patients on immunosuppressive therapy * rheumatoid arthritis or history of rheumatic disease * neurological deficits * malignant disease with or without metastases * significant liver function abnormalities * neurological or vascular insufficiency in the painful heel; fasciotomy or heel spur surgery * discrepancy in the length of the foot \> 5 mm; previous back of foot surgery * patients treated with rigid plantar supports

Keywords: fasciitis, plantar foot orthoses high-energy shock waves
non-closure of alveoli after avulsion of wisdom teeth

Conditions: Wisdom Tooth Avulsion

Summary: the main objective of this study is to evaluate postoperative pain (measured by visual analogue scale (vas) on day 2 post surgery) in patients operated for avulsion of four wisdom teeth under general anesthesia and for whom the resulting alveoli were not sutured versus a similar group of patients undergoing standard care (suturing for lower alveoli).

the secondary objectives of this study are to compare the following between the two study arms: a. pain at day 31 b. operative time c. edema d. trismus e. the occurrence of complications f. alveolar flap healing g. the impact of smoking on the occurrence of complications h. the consumption of analgesics and use of local pain remedies i. impact on quality of life

Eligibility criteria:
inclusion criteria: * the patient was correctly informed about the implementation of the study, its objectives, constraints and patient rights * the patient gave his/her free and informed signed consent * for patients under 18 years of age, the patient's parents (or legal guardian) must have given their free and informed signed consent * the patient must be affiliated with or the recipient of a health insurance program * the patient is available for 31 days of follow-up * the patient is a candidate for avulsion of all 4 wisdom teeth under general anesthesia exclusion criteria: * the patient is participating in another study * the patient has participated in another study in the last 3 months * the patient is in an exclusion period is determined by a previous study * the patient is an adult under guardianship * the patient is under judicial protection * the patient refuses to sign the consent * it is impossible to correctly inform the patient * for patients under 18 years of age, his/her parents (or legal guardian) refuse to sign the consent * the patient is pregnant, breastfeeding or parturient * the patient has a contra-indication (or an incompatible combination therapy) for a treatment in this study * the patient is taking antiplatelet agents * the patient is taking anticoagulants * the patient has a coagulation disorder * the patient suffers from immunosuppression * the patient's wisdom teeth are in a normal, functional, healthy position * other orofacial surgical procedures are planned during the study period * active pericoronitis

Keywords: to suture or not to suture.... tooth extraction third molar
registry on efficacy and safety of rosuvastatin, and atorvastatin and simvastatin in hypercholesterolaemia

Conditions: Hypercholesterolaemia

Summary: the objective of this follow-up retrospective study is to evaluate the long term efficacy and safety of rosuvastatin in reducing lipid parameters in clinical practice.


Eligibility criteria:
inclusion criteria: * primary hypercholesterolemia * subjects from first rosuvastatin registry study

Keywords: cholesterol rosuvastatin retrospective
clinical of hypersensitivity reduction efficacy on two toothpastes

Conditions: Hypersensitivity

Summary: to evaluate the clinical efficacy of a dual zinc toothpast containing 5% small particle size silica (ac43) as compared to colgate maxfresh tea toothpaste on dentin hypersensitivity reduction after brushing two times daily (morning and evening) for a period of 8 weeks


Eligibility criteria:
inclusion criteria: * male and female subjects, ages 18-70, inclusive. * availability for the eight-week duration of the study. * two sensitive teeth, which must be anterior to the molars, and demonstrate cervical erosion/abrasion or gingival recession. * qualifying response to tactile stimuli (yeaple probe) as defined by a score between 10-50 gms. of force. * qualifying response to the air blast stimuli as defined by a score of 2 or 3 on the schiff cold air sensitivity scale. * subjects need to satisfy the qualifying response to stimuli for both the parameters assessed (tactile or air) on two teeth to be entered into the study. * good general health with no known allergies to products being tested. * use of a non-desensitizing dentifrice for three months prior to entry into the study. * signed informed consent form. exclusion criteria: * gross oral pathology, chronic disease, or history of allergy to test products. * advanced periodontal disease or treatment for periodontal disease (including surgery) within the past twelve months. * sensitive teeth with a mobility greater than one. * teeth with extensive/defective restorations (including prosthetic crowns), suspected pulpitis, caries, cracked enamel, or used as abutments for removable partial dentures. * current use of anticonvulsants, antihistamines, antidepressants, sedatives, tranquilizers, anti-inflammatory drugs, or daily use of analgesics. * participation in a desensitizing dentifrice study or regular use of a desensitizing dentifrice within the past three months. * current participation in any other clinical study. * pregnant or lactating subjects. * allergies to oral care products, personal care consumer products, or their ingredients. * medical condition which prohibits not eating/drinking for 4 hours.
clinical evaluation on using personal face masks with spectacles versus contact lenses

Conditions: Myopia

Summary: the aim of this study was to explore satisfaction with vision correction and ease of use of pfm (personal face masks) in a group of spectacle wearers who were randomised to continue wearing spectacles or be fitted with daily disposable contact lenses.

this was a two arm parallel-group, randomised study. subjects wearing single vision spectacles were recruited to participate in the study. subjects were randomised to either continue to use their spectacles or to be fitted with the study daily disposable (dd) contact lens.

Eligibility criteria:
inclusion criteria: 1. they are aged between 18 and 40 years. 2. they understand their rights as a research subject and are willing and able to sign a statement of informed consent. 3. they are willing and able to follow the protocol. 4. they are a 'neophyte' (i.e. someone who has not worn contact lenses previously, with the exception for the purposes of a trial fitting). 5. they have a contact lens spherical prescription between +8.00d and -10.00d (inclusive) based on the ocular refraction. 6. they have a cylindrical correction of -0.75dc or less in each eye based on the ocular refraction. 7. they own and habitually wear single vision spectacles. 8. they are willing to be fitted with contact lenses and understand they may be randomised to either group. 9. they are willing to wear the contact lenses (if relevant) or spectacles for at least 8 hours per day, 5 days per week. 10. they are able to wear the supplied surgical masks for the majority of time that they need to wear pfm and will wear the pfm for at least one hour a day for at least four days per week. 11. they can attain at least 0.20 logmar distance high contrast visual acuity in each eye with the study lenses (if relevant) or spectacles. 12. they agree to not participate in other clinical research while enrolled on this study. exclusion criteria: 1. they have an ocular disorder which would normally contra-indicate contact lens 2. wear. 3. they have a systemic disorder which would normally contra-indicate contact lens wear. 4. they are using any topical medication such as eye drops or ointment. 5. they have had cataract surgery. 6. they have had corneal refractive surgery. 7. they have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus. 8. they are pregnant or breastfeeding. 9. they have any ocular abnormality which would, in the opinion of the investigator, normally contraindicate contact lens wear. 10. they have any infectious disease which would, in the opinion of the investigator, contraindicate contact lens wear or pose a risk to study personnel; or they have any immunosuppressive disease (e.g. hiv), or a history of anaphylaxis or severe allergic reaction. 11. they require significant ocular/face personal protective equipment beyond a personal face mask. 12. they have taken part in any other contact lens or care solution clinical trial or research, within two weeks prior to starting this study. 13. they have spectacles which are not within ±0.50d of their refractive error.
addiction-focused emdr in inpatients who use non-opioid drugs: a multiple baseline study

Conditions: Substance Use Disorders

Summary: rationale: it is well established that substance use disorders (sud) have severe health consequences. despite behavioral and pharmacological treatment options, relapse rates remain high. in particular, for non-opioid drugs, such as amphetamines, cocaine, base-coke and cannabis, established, evidence-based pharmacological options to reduce craving, to substitute substance use or to enforce abstinence are lacking. therefore, there is a need for effective interventions for patients who use non-opioid drugs to reach and maintain long-term abstinence. a potential interesting intervention is addiction-focused eye movement desensitization and reprocessing (af-emdr) therapy. however, the limited research on af-emdr therapy and mixed findings thus far prohibit clinical use. recently, on the basis of diverse findings thus far, an adjusted af-emdr therapy protocol has been developed.

objective: to investigate areas of uncertainty about a possible future pilot rct using af-emdr as an add-on intervention in inpatients who use non-opioid drugs and receive regular, inpatient addiction treatment, by determining: * feasibility. * potential clinical efficacy. study population: adults with a primary non-opioid use disorder, who are admitted to an inpatient addiction care clinic. a total of nine eligible participants will be allocated (allocation ratio 1:1:1) at random, in a non-concurrent fashion to one of three baseline durations. intervention: a total of four 90 min. sessions of af-emdr twice per week added to tau. main study parameters/endpoints: * feasibility issues. * changes in daily craving.

Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study, patients must meet the following criteria: diagnosis of tobacco use disorder according to the dsm-5 (american psychiatric association, 2013) criteria. age ≥ 18 years. good dutch language proficiency (based on clinical judgement). smoking, on average, ≥ 10 cigarettes per day pre-admission. a score of at least 5 on a scale from 0 to 10, for motivation and self-efficacy a planned inpatient stay of ≥ 4 weeks. written informed consent. exclusion criteria: a patient who meets any of the following criteria will be excluded from participation in this study: serious therapy interfering behavior or symptoms that also interfere with tau, based on clinical judgement (e. g. psychiatric or medical crisis that requires immediate intervention).

Keywords: addiction emdr non-opioid drug disorder
study evaluating rhapsody registry in patients with depression and anxiety

Conditions: Pain; Depression; Anxiety Disorder

Summary: the purpose of this study is to assess the prevalence of major depression and/or anxiety disorder in patients consulting the general practitioner with acute or chronic painful physical symptoms and to identify risk factors.


Eligibility criteria:
inclusion criteria: * outpatient must be at least 18 years of age * consulting a general practitioner for painful physical symptoms * written informed consent exclusion criteria: * patient is unable to understand and comply with procedures of the study * patient is unable to complete the patient ratings * patient has an acute pain with an obvious cause

Keywords: pain depression anxiety disorder
multiple dose study in cancer patients: safety and tolerability of bms-754807 in combination with paclitaxel and carboplatin in patients with advanced or metastatic solid tumors

Conditions: Advanced Solid Tumors; Metastatic Solid Tumors

Summary: a phase i dose escalation study to determine the safety, tolerability, pharmacodynamics and preliminary anti-tumor activity of bms-754807 in combination with chemotherapy drugs, paclitaxel and carboplatin, in patients with advanced or metastatic solid tumors. in addition, the study is expected to identify the recommended dose or dose range of bms-754807 in combination with paclitaxel and carboplatin for phase 2 studies


Eligibility criteria:
inclusion criteria: * subjects with advanced or metastatic solid tumors for whom carboplatin and paclitaxel is considered an appropriate therapy * ecog performance status 0-1 * at least 4 weeks between surgery or last dose prior anti-cancer therapy exclusion criteria: * symptomatic brain metastases * any disorder or dysregulation of glucose homeostasis {e.g. diabetes) * uncontrolled or significant cardiovascular disease * inadequate bone marrow, liver or kidney function * evidence of \> grade 1 peripheral neuropathy

Keywords: subjects with advanced or metastatic solid tumors or neoplasms
negative pressure wound therapy to reduce surgical site infection

Conditions: Patients Undergoing Hepatopancreatobiliary Surgery

Summary: the purpose of this study is to compare the rate of surgical site infection between traditional wound care and negative pressure wound therapy. wounds will be assessed 4-5 days after surgery and at the first clinic visit after surgery.


Eligibility criteria:
inclusion criteria: * female and male patients 18 years of age or older * scheduled for an elective surgery in either open crs or open hpbs. this includes, but is not limited to: ileocecectomy, right hemicolectomy, extended right hemicolectomy, transverse colectomy, left hemicolectomy, sigmoidectomy, proctectomy, low anterior resection, or abdominoperineal resection gastrectomy, hepatectomy, bile duct reconstruction, duodenectomy, pancreatectomy, pancreaticoduodenectomy, or pancreatic duct reconstruction exclusion criteria: * the need for emergency surgery. * the need for use of only laparoscopic surgery. * presence of bowel obstruction, strangulation, peritonitis or perforation. * the presence of local or systemic infection preoperatively. * asa class ≥4. * inability to provide informed consent and authorization. * known allergy or hypersensitivity to silver. * any clinically significant condition that, in the investigator's opinion, would significantly impair the subject's ability to comply with the study.
comparative analgesic effects of paracetamol/codeine and ibuprofen on pain after third molar surgery

Conditions: To Control Pain After Third Molar Surgery

Summary: to compare analgesic effects of preoperative administration of paracetamol 500 milligram plus codeine 30 milligram in single-tablet and effervescent formulation to ibuprofen 400 milligram, and placebo in the management of moderate to severe postoperative pain after mandibular third molar surgery.

materials and methods: one hundred twenty healthy outpatients aged 15 to 29 years undergoing surgical removal of one bony impacted mandibular third molar were enrolled in this, single-center, prospective, randomized, triple-blind parallel-group, placebo-controlled, clinical trial. study participants were randomly assigned to three treatment arms. according to the concealed allocation, each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg (group a), ibuprofen 400 mg (group b) or placebo (group c). rescue therapy allowed in the postoperative period was paracetamol 500 mg plus codeine 30 mg in groups a and c and ibuprofen 400 mg in group b. patients recorded on numerical rating scale-11 (nrs-11) the pain intensity, total number of postoperative-supplement medications and time of the first intake, until 12-hours after surgery and over extra two days

Eligibility criteria:
inclusion criteria: * healthy status (asa class i); * nonsmoker; * not pregnant or breastfeeding; * no medication consumption in the past 21 days; * good oral hygiene; * bony impaction of one mandibular third molars; * the presence of the first and second molars; * compliance to cooperate with the research protocol. exclusion criteria: * chronic systemic disease; * medications with potential interaction to paracetamol-codeine or ibuprofen; * a history of intolerance or hypersensitivity to the study drugs; * any pre-existing pain and acute inflammatory or infectious conditions; - inability to understand or perform the study procedure.

Keywords: postsurgical dental pain
personalized prrt of neuroendocrine tumors

Conditions: Neuroendocrine Tumors; Carcinoid Tumor; Carcinoma, Neuroendocrine

Summary: in this study, peptide receptor radionuclide therapy (prrt) with 177lu-octreotate (lutate) will be personalized, i.e. administered activity of lutate will be tailored for each patient to maximize absorbed radiation dose to tumor, while limiting that to healthy organs. the purpose of this study is to: * assess the objective (radiological), symptomatic and biochemical response rates following an induction course of personalized prrt; * assess the overall, the disease-specific, and the progression-free survival following p-prrt; * correlate therapeutic response and survival with tumor absorbed radiation dose; * evaluate the acute, subacute and chronic adverse events following p-prrt; * correlate toxicity (i.e. occurence and severity of adverse events) with absorbed radiation doses to organs at risk; * optimize the quantitative spect imaging-based dosimetry methods in a subset of 20 patients (sub-study funded by the canadian institutes of health research). this study also has a compassionate purpose, which is to provide access to prrt to patients.

a prospective, single-center, non-comparative, open phase 2 study. in this study, personalized peptide receptor radionuclide therapy (p-prrt) with 177lu-octreotate (lutate) will be administered to patients with progressive and/or symptomatic inoperable neuroendocrine tumors (net) of any origin expressing the somatostatin receptor. the primary objective to assess the objective response rate at 3 months following a four-cycle induction course of p-prrt will be assessed for at least the first 85 participants. this study as a compassionate aim to provide access to personalized prrt patients at chu de québec - université laval center, and therefore this study has no pre-determined recruitment period duration or limited number of participants, and may remain open as long as necessary to fulfill this aim. the study will continue until all participants have completed a minimum follow-up of 5 years. interim analyses will be conducted annually.

Eligibility criteria:
inclusion criteria: * patient suffering from a progressive and/or symptomatic net (any site); * patient ineligible to, or refusing a potentially curative treatment such as surgical resection; * patient who did not respond, is intolerant or refuses other indicated and available palliative treatments; * demonstration of overexpression of somatostatin receptor by tumor lesions by scintigraphic imaging (octreoscan or 68ga positron emission tomography. exclusion criteria: * pregnancy; * breastfeeding;. * very limited survival prognosis (i.e. less than a few weeks, because of the net disease or any other condition) or eastern cooperative oncology group (ecog) 4 performance status; * inability to obtain informed consent of the participant.

Keywords: neuroendocrine tumors personalized peptide receptor radionuclide therapy prrt 177lu-dotatate 177lu-octreotate
pf-07225570 alone or in combination with an anti-pd-1 antibody in recurrent non-muscle invasive bladder cancer (nmibc)

Conditions: Bladder Cancer

Summary: the primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of pf-07225570 alone or in combination with an anti-pd-1 antibody in participants with recurrent non-muscle invasive bladder cancer. this study consists of 2 parts, single agent dose escalation (part 1a), dose finding of pf-07225570 in combination with anti-pd-1 antibody (part 1b) and dose expansion (part 2).


Eligibility criteria:
inclusion criteria: histological confirmed and documented diagnosis of non-muscle invasive urothelial carcinoma participants with recurrent non-muscle invasive bladder cancer (intermediate risk or high risk) ineligible for or elected not to undergo radical cystectomy no evidence of upper tract urothelial cancer or cancer within the prostatic urethra as documented by imaging studies performed within 6 months of enrollment eastern cooperative oncology group (ecog) performance status 0-1 adequate bone marrow, renal and liver function exclusion criteria: evidence of muscle-invasive, locally advanced or metastatic urothelial carcinoma or concurrent extravesical, non-muscle invasive urothelial carcinoma macroscopic hematuria, traumatic catheterization or active urinary tract infection active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) hepatitis b, hepatitis c, and known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness

Keywords: recurrent non-muscle invasive bladder cancer (nmibc) urothelial cancer toll-like receptor 7 (tlr7) toll-like receptor 8 (tlr8)